A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-02-23
Target enrollment:
Participant gender:
Summary
To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237
when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by
a 14-day recovery period.